Top

Published in:

Open Access 01-12-2018 | Commentary

Off-label drugs use in pediatric palliative care

Published in: Italian Journal of Pediatrics | Issue 1/2018

Abstract

Background

Paediatric palliative care (PPC) aim to ensure the control of symptoms and the best possible quality of life for patients whose underlying disease, characterized by an unstoppable evolution and negative prognosis, no longer responds to specific treatments. The scientific evidence in this context are very deficient and, in order to obtain welfare objectives consistent with the situation, in the overwhelming majority of cases the prescription of drugs is off-label for indication of use and/or for age and/or for way of administration and/or formulation.

The Agenzia Italiana del Farmaco - AIFA and the Italian Society of Palliative Care (Società Italiana di Cure Palliative - SICP), under a dedicated working group, wrote a document that collects the scientific evidence available to support the off-label use of medicines more frequently used in PPC. The goal is to certify the consolidated off-label use of these drugs and propose their use under the Law 648/96, in the absence of data from its pivotal clinical trials.

Aim of the commentary is to report the conditions for this important work and to present the 10 drugs, usually used off-label in PPC and in pain therapy, now included in Law 648/96.

Conclusion

This work is deemed essential to resolve, at least in part, the lack of availability of medicines researched and approved.

European Union. Regulation (EC) N° 1901/2006 on Medicinal Products for Paediatric Use and Amending Regulation (EEC) N° 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) N° 726/2004. Available at: http://ec.europa.eu/health/human-use/paediatric-medicines/index_en.htmOR http://eur-lex.europa.eu/RECH_legislation.do.

European Medicines Agency. Updated priority list (revised) for studies into off-patent paediatric medicinal products. Doc. Ref. EMA/197972/2007. London: EMA, 2007.

Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr. 2005;164(9):552–8.CrossRef

Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf. 2006;5(5):703–718. 2.CrossRef

Gore R, Chugh PK, Tripathi CD, Lhamo Y, Gautam S. Pediatric off-label and unlicensed drug use and its implications. Curr Clin Pharmacol. 2017;12(1):18–25.CrossRef

Barker CIS, Standing JF, Kelly LE, Hanly Faught L, Needham AC, Rieder MJ, de Wildt SN, Offringa M. Pharmacokinetic studies in children: recommendations for practice and research. Arch Dis Child. 2018;103(7):695–702. https://doi.org/10.1136/archdischild-2017-314506 [Epub ahead of print].

Steinbrook R. Testing medications in children. N Engl J Med. 2002;347(18):1462–70.CrossRef

American Academy of Pediatrics Committee on Drugs. Uses of drugs not described in the package insert (off-label uses). Pediatrics. 2002;110(1 pt 1):181–3 pmid:12093968.CrossRef

Rocchi F, Paolucci P, Ceci A, Rossi P. The European paediatric legislation: benefits and perspectives. Ital J Pediatr. 2010;36:56. https://doi.org/10.1186/1824-7288-36-56.CrossRef

10.

Rossi F, Marchetti F. European Paediatric regulation on drugs. Medico e Bambino. 2013;32:519–24.

11.

Tomasi PA, Egger GF, Pallidis C, Saint-Raymond A. Enabling development of Paediatric medicines in Europe: 10 years of the EU Paediatric regulation. Paediatr Drugs. 2017;19(6):505–13. https://doi.org/10.1007/s40272-017-0261-1.CrossRefPubMed

12.

Frattarelli DA, Galinkin JL, Green TP, American Academy of Pediatrics Committee on drugs, et al. Off-label use of drugs in children. Pediatrics. 2014;133(3):563–7.CrossRef

13.

Marchetti F, Bua J, Ventura A, Notarangelo LD, Di Maio S, Migliore G, Bonati M. The awareness among paediatricians of off-label prescribing in children: a survey of Italian hospitals. Eur J Clin Pharmacol. 2007;63(1):81–5.CrossRef

14.

Bonati M, Jacqz-Aigrain E, Choonara I. Licensed medicines, off-label use or evidence-based. Which is most important? Arch Dis Child. 2017;102(1):53–4.CrossRef

15.

Luedtke KE, Buck ML. Evaluation of off-label prescribing at a Children’s rehabilitation center. J Pediatr Pharmacol Ther. 2014;19(4):296–301. https://doi.org/10.5863/1551-6776-19.4.296.CrossRefPubMedPubMedCentral

16.

Kwon JH, Kim MJ, Bruera S, Park M, Bruera E, Hui D. Off-label medication use in the inpatient palliative care unit. J Pain Symptom Manag. 2017;54(1):46–54. https://doi.org/10.1016/j.jpainsymman.2017.03.014.CrossRef

17.

Fraser J, Harris N, Berringer AJ, Prescott H, Finlay F. Advanced care planning in children with life-limiting conditions - the wishes document. Arch Dis Child. 2010;95(2):79.CrossRef

18.

Benini F, Orzalesi M, de Santi A, Congedi S, Lazzarin P, Pellegatta F, De Zen L, Spizzichino M, Alleva E. Barriers to the development of pediatric palliative care in Italy. Ann Ist Super Sanita. 2016;52(4):558–64. https://doi.org/10.4415/ANN_16_04_16.CrossRefPubMed

19.

Jamieson L, Wong IC, Craig F, Christiansen N, Brombley K, Tuleu C, Harrop E. Palliative medicines for children - a new frontier in paediatric research. J Pharm Pharmacol. 2017;69(4):377–83.CrossRef

20.

AIFA. Legge 648/96. http://www.agenziafarmaco.gov.it/content/legge-64896

21.

Working Group Pediatrico dell’ AIFA. The first list of cardiovascular drugs authorized in paediatrics. Medico e Bambino. 2010;29:172–6.

22.

Salvo I, Landoni G, Mucchetti M, Cabrini L, Pani L. Use and reimbursement of off-label drugs in pediatric anesthesia: the Italian experience. Pediatr Anesth. 2014;24:625–31.CrossRef

23.

Società Italiana di Cure Palliative (SICP) e dall’Agenzia Italiana del Farmaco (AIFA) (Estensori del documento: Benini F, De Zen L, Marchetti F, Barbi E). Farmaci off-label in cure palliative (CP) per la popolazione pediatrica. http://www.aifa.gov.it/sites/default/files/OffLabel_pediatrica.pdf

24.

British National Formulary (BNF) for children, ed. 2016/2017.

25.

Cozzi G, Norbedo S, Barbi E. Intranasal Dexmedetomidine for procedural sedation in children, a suitable alternative to chloral hydrate. Paediatr Drugs. 2017;19(2):107–11. https://doi.org/10.1007/s40272-017-0217-5.CrossRefPubMed

26.

Goldman A, Hain R, Liben S. Oxford Textbook of Palliative Care for Children 2nd edition. New York: Oxford University Press Inc.,; 2012.

27.

Wolfe J, Hinds PS, Sourkes BM. Textbook of Interdisciplinary Pediatric Palliative Care. Philadelphia: Elsevier Saunders; 2011.CrossRef

28.

Poonai N, Canton K, Ali S, Hendrikx S, et al. Intranasal ketamine for procedural sedation and analgesia in children: a systematic review. PLoS One. 2017;12(3):e0173253. https://doi.org/10.1371/journal.pone.0173253 eCollection 2017.CrossRefPubMedPubMedCentral

29.

Mehran M, Tavassoli-Hojjati S, Ameli N, et al. Effect of Intranasal Sedation Using Ketamine and Midazolam on Behavior of 3-6 Year-Old Uncooperative Children in Dental Office: A Clinical Trial. J Dent (Tehran). 2017;14(1):1–6 PMID 28828011.

30.

Scheier E, Siman A, Balla U. Intranasal ketamine proved feasible for pain control in paediatric care and parental support was high. Acta Paediatr. 2017;106(10):1702. https://doi.org/10.1111/apa.13965 [Epub ahead of print].CrossRef

31.

Carr DB, Goudas LC, Denman WT, et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain. 2004;108(1–2):17–27 PMID15288418.CrossRef

32.

Neri E, Maestro A, Minen F, Montico M, et al. Sublingual ketorolac versus sublingual tramadol for moderate to severe post-traumatic bone pain in children: a double-blind, randomised, controlled trial. Arch Dis Child. 2013;98:721–4.CrossRef

33.

Molassiotis A, Smith JA, MAzzone P, et al. Symptomatic treatment of cough among adult patients with lung Cancer: CHEST guideline and expert panel report. Chest. 2017;151(4):861–74. https://doi.org/10.1016/j.chest.2016.12.028.CrossRefPubMedPubMedCentral

34.

Kajiume T, Sera Y, Nakanuno R, Ogura T, et al. Continuous intravenous infusion of ketamine and lidocaine as adjuvant analgesics in a 5-year-old patient with neuropathic cancer pain. J Palliat Med. 2012;15(6):719–22. https://doi.org/10.1089/jpm.2011.0097 Epub 2012 Mar 8.CrossRefPubMed

35.

Stokland E, Andreasson S, Jacobsson B, et al. Sedation with midazolam for voiding cystourethrography in hcildren: a randomised double-blind study. Pediatr Radio. 2003;33:247–9. https://doi.org/10.1007/s00247-003-0874-0.CrossRef

36.

Chiaretti A, Barone G, Rigante D, Ruggiero A, Pierri F, Barbi E, Barone G, Riccardi R. Intranasal lidocaine and midazolam for procedural sedation in children. Arch Dis Child. 2011;96(2):160–3. https://doi.org/10.1136/adc.2010.188433 Epub 2010 Oct 27.CrossRef

Title: Off-label drugs use in pediatric palliative care
Publication date: 01-12-2018
Published in: Italian Journal of Pediatrics / Issue 1/2018
Electronic ISSN: 1824-7288
DOI: https://doi.org/10.1186/s13052-018-0584-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Off-label drugs use in pediatric palliative care

Abstract

Background

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Role of sleep duration and sleep-related problems in the metabolic syndrome among children and adolescents

Methylenetetrahydrofolate reductase polymorphism (MTHFR C677T) and headache in children: a retrospective study from a tertiary level outpatient service

Pleural effusion from intrathoracic migration of a ventriculo-peritoneal shunt catheter: pediatric case report and review of the literature

Gambling disorder in adolescents: what do we know about this social problem and its consequences?

Acute malnutrition among children aged 6–59 months of the nomadic population in Hadaleala district, Afar region, northeast Ethiopia

Management of undescended testis may be improved with educational updates and new transferring model